The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys


Cite item

Full Text

Abstract

Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK). However, its long-term use often results in hypercalciemia with metastatic calcification. Compared to calcitriol, paricalcitol (zemplar) - metabolite of vitamin D2 - leads to hypercalciemia less frequently, has a more potent nephroprotective effect and more rapidly decreases blood levels of parathyroid hormone. Paricalcitol in combination with lozartan has more pronounced nephroprotective effect. Morphological analysis detected inhibition of development of glomerulosclerosis and tubulointerstitial fibrosis. A cardioprotective effect of paricalcitol manifests with reduction of mortality from cardiovascular complications both at CDK predialysis stage and in regular hemodialysis.

About the authors

Yuriy Sergeevich Milovanov

Email: yumil2010@rambler.ru

Lidiya Vladimirovna Kozlovskaya

Email: lkoslovckay@mail.ru

Lyudmila Yur'evna Milovanova

Email: lussya2000@mail.ru

Yu S Milovanov

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

L V Kozlovskaya

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

L Yu Milovanova

I.M. Sechenov First Moscow State Medical University

I.M. Sechenov First Moscow State Medical University

References

  1. Agarwal R., Acharya M., Tian J. et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68 (6): 2823-2828.
  2. Coyne D., Acharya M., Qiu P. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 2006; 47 (2): 263-276.
  3. Krajisnik T., Bjorklund P., Marsel R. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1-alfa-hydroxylaseexpression in cultured bovine parathyroid cells. J. Endocrinol. 2007; 195: 125-131.
  4. Sprague S. M., Liach F., Amdahl M. et al. Paricacitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 64 (4): 1483-1490.
  5. Lindberg J., Martin K. J. et al. A long-term, multicenter study of the efficacy and safety of parycalcitol in end-stage renal disease. Clin. Nephrol. 2001; 56 (4): 315-323.
  6. Teng M., Wolf M., Lowrie E. et al. Survival of patients undergoing hemodialysis with paricacitol or calcitriol therapy. N. Engl. J. Med. 2003; 349 (5): 446-456.
  7. Martin K. J., Gonzalez M. G. et al. 19-Nor-1-a-25 Dihydroxyvitamin D2 (Paricalcitol) safety and affectively reduces the levels of the intact Parathyroid Hormone in patients on Hemodialysis. J. Am. Soc. Nephrol. 1998; 9: 1427-1432.
  8. Liach F., Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am. J. Kidney Dis. 2001; 38 (Suppl. 5): S45-S50.
  9. Schumock G. T. Comparative effectiveness of aricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin. Pract. 2010; 117 (2): 151-159.
  10. Dobrez D. G., Mathes A., Amdahl M. et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitrioltreated patients in real-world clinical settings. Nephrol. Dial. Transplant. 2004; 19: 1174-1181.
  11. Schumack G. T., Arruda J. A. L., Marx S. E. et. al. Economic comparison of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism impact of hospitalization and survival. J. Med. Econ. 2007; 10: 393-409.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies